145 related articles for article (PubMed ID: 30665930)
1. Clinical features of scleromyxoedema in an Afro-Caribbean man.
Ufodiama CE; Tynes G; Unwala R
BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30665930
[No Abstract] [Full Text] [Related]
2. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy.
Manousaridis I; Loeser C; Goerdt S; Hassel JC
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec; 19(4):15-9. PubMed ID: 21390475
[TBL] [Abstract][Full Text] [Related]
3. Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin.
Körber A; Franckson T; Grabbe S; Dissemond J
J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):553-4. PubMed ID: 17373996
[No Abstract] [Full Text] [Related]
4. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
Mahévas T; Arnulf B; Bouaziz JD; Livideanu CB; Osio A; Servy A; Cribier B; Sassolas B; Jachiet M; Michel L; Aucouturier P; Lipsker D; Frances C; Sbidian E; Rybojad M; Descamps V; D'Incan M; Humbert P; Beylot-Barry M; Passeron T; de Moreuil C; Taha RY; Hermine O; Dupuy A; Barbarot S; Debarbieux S; Carpentier O; Brault F; Schmutz JL; Thomas-Beaulieu D; Modiano P; Zarnitsky C; Lifermann F; Baubion E; Limal N; Le Bras F; Le Moigne M; Tauber M; Talbot A; Prud'homme R; Peltier S; De Masson A; Battistella M; Bagot M; Mékinian A; Fain O
Blood; 2020 Apr; 135(14):1101-1110. PubMed ID: 32027747
[TBL] [Abstract][Full Text] [Related]
5. Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes.
Bidier M; Zschoche C; Gholam P; Enk AH; Hadaschik EN
Acta Derm Venereol; 2012 Jul; 92(4):408-9. PubMed ID: 22278389
[No Abstract] [Full Text] [Related]
6. Scleromyxedema with histology resembling granuloma annulare.
Mullangi S; Granter SR; Laubach JP; Lipworth AD
Dermatol Online J; 2014 Dec; 21(3):. PubMed ID: 25780962
[TBL] [Abstract][Full Text] [Related]
7. Acute Encephalitic Syndrome Induced by Scleromyxedema.
Magira EE; Malouchou A; Karathanasi V; Mavropoulou N; Siempos II; Vourlakou C; Sykaras A; Anastasiadis G
Am J Med Sci; 2020 Aug; 360(2):192-195. PubMed ID: 32540147
[TBL] [Abstract][Full Text] [Related]
8. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients.
Rongioletti F; Merlo G; Cinotti E; Fausti V; Cozzani E; Cribier B; Metze D; Calonje E; Kanitakis J; Kempf W; Stefanato CM; Marinho E; Parodi A
J Am Acad Dermatol; 2013 Jul; 69(1):66-72. PubMed ID: 23453242
[TBL] [Abstract][Full Text] [Related]
9. Scleromyxoedema: the importance of physical examination.
Pipa S; Sá J; Mondragão A; Marinho A
BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30317211
[No Abstract] [Full Text] [Related]
10. sQUIZ your knowledge: Widespread millimetric papules in a patient with monoclonal gammopathy.
Iglesias-Puzas Á; Rodríguez-Jato Q; Flórez Á
Eur J Dermatol; 2019 Apr; 29(2):244-245. PubMed ID: 31106768
[No Abstract] [Full Text] [Related]
11. Rare case of infiltrative cardiomyopathy secondary to scleromyxoedema.
Khandkar C; Vaidya K; Penglase R; Cai K; Shin JS; Hunyor I; Keech A; McGill N
Intern Med J; 2020 Jan; 50(1):127-128. PubMed ID: 31943623
[No Abstract] [Full Text] [Related]
12. [Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study].
Le Moigne M; Mazereeuw-Hautier J; Bonnetblanc JM; Astudillo L; D'Incan M; Bessis D; Thomas L; Debarbieux S; Ammoury A; Lamant L; Paul C
Ann Dermatol Venereol; 2010 Dec; 137(12):782-8. PubMed ID: 21134580
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Efficacy of Treatment with Intravenous Immunoglobulin in Scleromyxedema.
Baglama Š; Trčko K
Acta Dermatovenerol Croat; 2020 Jul; 28(1):24-28. PubMed ID: 32650847
[TBL] [Abstract][Full Text] [Related]
14. Scleromyxedema.
Bogner RR; Wetter DA; Dingli D
Intern Med; 2014; 53(21):2561-2. PubMed ID: 25366027
[No Abstract] [Full Text] [Related]
15. Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.
Wang SS; Chen QY; Xiang LH
Front Immunol; 2022; 13():1099918. PubMed ID: 36713453
[TBL] [Abstract][Full Text] [Related]
16. Scleromyxedema.
Chatterjee S; Fernandez AP
N Engl J Med; 2023 Nov; 389(21):1992. PubMed ID: 37991858
[No Abstract] [Full Text] [Related]
17. [Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin].
Topf S; Simon M; Schell H; Lüftl M
Hautarzt; 2007 Jun; 58(6):525-8. PubMed ID: 17165069
[TBL] [Abstract][Full Text] [Related]
18. [Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses--scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies].
Adam Z; Szturz P; Krejčí M; Vašků V; Pour L; Michalková E; Ševčíková S; Čermáková Z; Veselý K; Vaníček J; Pourová E; Král Z; Mayer J
Vnitr Lek; 2015 Dec; 61(12):1072-87. PubMed ID: 26806503
[TBL] [Abstract][Full Text] [Related]
19. Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy.
Delyon J; Bézier M; Rybojad M; Brière J; Validire P; Bagot M; Janin A; Battistella M
Virchows Arch; 2013 Jun; 462(6):679-83. PubMed ID: 23681113
[TBL] [Abstract][Full Text] [Related]
20. [Scleromyxedema with neurological symptoms: successful treatment with immunoglobulins].
Manríquez J; Berroeta-Mauriziano D; Andino-Navarrete R; Vera-Kellet C
Med Clin (Barc); 2015 Jan; 144(1):47-8. PubMed ID: 24656121
[No Abstract] [Full Text] [Related]
[Next] [New Search]
